Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML

Next-generation sequencing (NGS) has been applied to measurable/minimal residual disease (MRD) monitoring after induction chemotherapy in patients with acute myeloid leukemia (AML), but the optimal time point for the test remains unclear. In this study, we aimed to investigate the clinical significance of NGS MRD at 2 different time points. We performed targeted NGS of 54 genes in bone marrow cells serially obtained at diagnosis, first complete remission (first time point), and after the first consolidation chemotherapy (second time point) from 335 de novo AML patients. Excluding DNMT3A, TET2, and ASXL1 mutations, which are commonly present in individuals with clonal hematopoiesis of indeterminate potential, MRD could be detected in 46.4% of patients at the first time point (MRD1st ), and 28.9% at the second time point (mRD2nc.) The patients with detectable NGS MRD at either time point had a significantly higher cumulative incidence of relapse and shorter relapse free survival and overall survival. In multivariate analysis, MRD1st and MRD2nd were both independent poor prognostic factors. However, the patients with positive MRD1st but negative MRD2nd had a similar good prognosis as those with negative MRD at both time points. The incorporation of multiparameter flow cytometry and NGS MRD revealed that the presence of NGS MRD predicted poorer prognosis among the patients without detectable MRD by multiparameter flow cytometry at the second time point but not the first time point. In conclusion, the presence of NGS MRD, especially after the first consolidation therapy, can help predict the clinical outcome of AML patients.

Automated summary

This study demonstrated the clinical significance of measuring NGS MRD in AML patients, especially predicting clinical outcome after the first consolidation therapy. Patients with detectable MRD at both time points had poorer prognosis, while those with positive MRD1st but negative MRD2nd showed similar good prognosis as those with negative MRD at both time points. Incorporating NGS MRD testing, particularly after the first consolidation therapy, can help predict the clinical outcome of AML patients.